Boule Diagnostics AB - Asset Resilience Ratio
Boule Diagnostics AB (BOUL) has an Asset Resilience Ratio of 4.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BOUL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Boule Diagnostics AB's Asset Resilience Ratio has changed over time. See net asset quality index of Boule Diagnostics AB to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Boule Diagnostics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Boule Diagnostics AB (BOUL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr23.00 Million | 4.94% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr23.00 Million | 4.94% |
Asset Resilience Insights
- Limited Liquidity: Boule Diagnostics AB maintains only 4.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Boule Diagnostics AB Industry Peers by Asset Resilience Ratio
Compare Boule Diagnostics AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Boule Diagnostics AB (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Boule Diagnostics AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.48% | Skr26.43 Million ≈ $2.84 Million |
Skr590.20 Million ≈ $63.51 Million |
-0.45pp |
| 2023-12-31 | 4.93% | Skr37.23 Million ≈ $4.01 Million |
Skr755.11 Million ≈ $81.26 Million |
-1.80pp |
| 2022-12-31 | 6.73% | Skr51.11 Million ≈ $5.50 Million |
Skr759.96 Million ≈ $81.78 Million |
+6.49pp |
| 2021-12-31 | 0.24% | Skr1.36 Million ≈ $146.36K |
Skr572.03 Million ≈ $61.56 Million |
+1.04pp |
| 2020-12-31 | -0.80% | Skr-3.83 Million ≈ $-411.85K |
Skr479.71 Million ≈ $51.62 Million |
+3.58pp |
| 2019-12-31 | -4.38% | Skr-25.70 Million ≈ $-2.77 Million |
Skr586.87 Million ≈ $63.16 Million |
-2.21pp |
| 2018-12-31 | -2.17% | Skr-10.86 Million ≈ $-1.17 Million |
Skr500.85 Million ≈ $53.90 Million |
-25.98pp |
| 2017-12-31 | 23.81% | Skr99.16 Million ≈ $10.67 Million |
Skr416.49 Million ≈ $44.82 Million |
+11.57pp |
| 2016-12-31 | 12.24% | Skr44.59 Million ≈ $4.80 Million |
Skr364.33 Million ≈ $39.21 Million |
-30.74pp |
| 2010-12-31 | 42.98% | Skr88.58 Million ≈ $9.53 Million |
Skr206.11 Million ≈ $22.18 Million |
-- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more